Protocol Ledger

NCT05012397 · Phase II · TERMINATED

Milademetan in Advanced/Metastatic Solid Tumors

Interventional Phase II clinical trial protocol NCT05012397 sponsored by Rain Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-01 Enrollment: 40 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05012397
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05012397
Protocol FieldVerified Registry Value
NCT IdentifierNCT05012397
Consolidated Lead SponsorRain Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment40 participants (ACTUAL)
Registered Start Date2021-11-01
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI